Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 12
The role of NMDAR antibody in the etiopathogenesis of schizophrenia
Authors Timucin D, Ozdemir O, Parlak M
Received 30 May 2016
Accepted for publication 28 July 2016
Published 13 September 2016 Volume 2016:12 Pages 2327—2332
DOI https://doi.org/10.2147/NDT.S113872
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Roger Pinder
Damla Timucin,1 Osman Ozdemir,2 Mehmet Parlak3
1Department of Psychiatry, University of Health Sciences, Van Training and Research Hospital, Van, 2Department of Psychiatry, 3Department of Microbiology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey
Abstract: Many authors have reported the presence of serum NMDAR antibodies in varying proportions of patients with schizophrenia; however, many others have not been able to confirm this. Because of the contradictory findings reported in various studies, more definitive research on this issue is required. Hence, we have investigated the NR1 subunit of NMDAR antibodies in patients with schizophrenia (n=49) and healthy controls (n=48). None of the investigated patients with schizophrenia and none of the healthy controls showed positive antibody against the NR1 subunit of the NMDAR. On the basis of this result, we conclude that the NR1 subunit of the NMDAR antibodies does not seem to have a role in schizophrenia.
Keywords: schizophrenia, N-acetyl d-aspartate receptor, glutamate, antibody
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.